Sangamo Therapeutics

Update in progress

SGMO (PNK)

Company RatingNeutral
SectorHealthcare
IndustryBiotechnology

Sangamo Therapeutics is a clinical-stage genomic medicine company translating science into medicines for serious diseases. Its candidates include ST-920 (Phase 1/2) for Fabry disease, small fiber neuropathy, and prion disease; TX200 cell therapy (Phase 1/2) for kidney transplant patients; SB-525 (Phase 3) for hemophilia A; and giroctocogene fitelparvovec (Phase 3) for hemophilia A. It partners with Genentech, Astellas, Eli Lilly, Alexion, Takeda, and others. Formerly Sangamo BioSciences; renamed 2017.

Company score

Sentiment: -0.48; SentimentMeasures the overall tone of recent coverage and discussion about the company.−10 negative · 0 neutral · +10 positive
Environment: 0.00; EnvironmentAssesses the company’s environmental impact, risks, and sustainability practices.−10 negative · 0 neutral · +10 positive
Social: -0.04; SocialAssesses the company’s influence on employees, customers, communities, and wider society.−10 negative · 0 neutral · +10 positive
Governance: -0.41; GovernanceAssesses leadership, accountability, transparency, and business ethics.−10 negative · 0 neutral · +10 positive
Sustainability: -0.10; SustainabilityCombines environmental, social, and governance signals into an overall sustainability score.−10 negative · 0 neutral · +10 positive
Impact Score: -0.29; Impact ScoreCombines sentiment and sustainability performance into an assessment of the company’s overall impact.−10 negative · 0 neutral · +10 positive